Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04471415
Recruitment Status : Recruiting
First Posted : July 15, 2020
Last Update Posted : April 13, 2021
Sponsor:
Information provided by (Responsible Party):
Dracen Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat) administered via intravenous infusion or via subcutaneous injection as a single agent and in combination with atezolizumab in patients with advanced solid tumors and to assess preliminary safety and efficacy of which route of administration (intravenous or subcutaneous) will be selected for further development for the other two expansions of patients, advanced non-small cell lung cancer (NSCLC) with defined genetic mutations, and advanced squamous cell carcinoma of the head and neck (SCCHN).

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Non-Small Cell Lung Cancer Recurrent Squamous Cell Carcinoma of Head and Neck Non Small Cell Lung Cancer Metastatic Drug: DRP-104 Biological: atezolizumab Phase 1 Phase 2

Detailed Description:

This study will be conducted in 4 Parts:

Part 1: Phase 1 single-agent dose escalation of DRP-104 (sirpiglenastat) in patients with advanced solid tumors to define the MTD (up to approximately 50 patients for each intravenous and subcutaneous cohort)

Part 2, Once the MTD of DRP-104 for the IV and subQ route of administration will be determined in Part 1, Part 2 will include 2 specific cohorts: Cohort 2 and 3 with one only selected formulation. Once the MTD of DRP-104 has been declared for either the IV or suQ cohort, Cohort 1 of Part 2 will separately expand for each cohort. -Cohort 1: Phase 1 single-agent safety expansion at the of DRP-104 in patients with advanced solid tumors (N= minimum of 14 and up to 20 patients for each intravenous and subcutaneous cohorts); The Sponsor will determine at completion of Phase 1 which route of administration will be further developed and continued for all subsequent Cohorts 2 and 3 and Parts 3 and Part 4 in combination with atezolizumab.

  • Cohort 2: Phase 2a expansion at the of DRP-104 in patients with locally advanced or metastatic NSCLC whose tumors contain a KEAP1 mutation, NFE2L2 mutation and/or STK11 mutation (N=55 patients)
  • Cohort 3: Phase 2a expansion at the MTD of DRP-104 in recurrent, unresectable or metastatic SCCHN (N=15-25 patients).

Part 3: Phase 1 combination dose escalation of DRP-104 (sirpiglenastat) (with either IV or subcutaneous formulation selected) and atezolizumab in patients with advanced solid tumors previously treated with an anti-PD-1, anti PD-L1, and/or anti-CTLA-4 antibody, starting one dose level below the MTD of single-agent DRP-104 and in combination with atezolizumab (up to approximately N=12 patients).

Part 4: Phase 1 combination safety expansion at the MTD of DRP-104 (with either IV or subcutaneous formulation selected)with atezolizumab in a similar patient population as the dose-escalation (N=14 patients).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 246 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose Escalation cohort, followed by Dose Expansion cohort, followed by NSCLC, SCCHN and combination with atezolizumab cohorts.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 and Phase 2a, First-in-human Study of DRP-104 (Sirpiglenastat), a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Actual Study Start Date : August 31, 2020
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1a & Part 1b

Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 of 3.3 mg/m2 via intravenous injection

Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 at 10 mg via subcutaneous injection

Drug: DRP-104

DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off

DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week


Experimental: Part 2
  • Cohort 1a: Phase 1 single-agent safety expansion at the of intravenous DRP-104 in patients with advanced solid tumors (N=14 up to 20 patients);
  • Cohort 1b: Phase 1 single-agent safety expansion at the of subcutaneous DRP-104 in patients with advanced solid tumors (N=14 up to 20 patients);
  • Cohort 2: Phase 2a expansion at the of DRP-104 at the recommended selected route of administration (intravenous or subcutaneous) in patients with locally advanced or metastatic NSCLC whose tumors contain a KEAP1 mutation, NFE2L2 mutation and/or STK11 mutation (N=55 patients)
  • Cohort 3: Phase 2a expansion at the MTD of DRP-104 at the recommended selected route of administration (intravenous or subcutaneous) in recurrent, unresectable or metastatic SCCHN (N=15-25 patients).
Drug: DRP-104

DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off

DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week


Experimental: Part 3
Dose escalation of DRP-104 at 1 dose level below declared MTD at the selected recommended route of administration (intravenous or subcutaneous) in combination with atezolizumab in patients with advanced solid tumors previously treated with an anti-PD-1, anti PD-L1, and/or anti-CTLA-4 antibody (up to approximately (N=12 patients).
Drug: DRP-104

DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off

DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week


Biological: atezolizumab
atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.

Experimental: Part 4
Dose expansion at the MTD of DRP-104 at the selected recommended route of administration (intravenous or subcutaneous) with atezolizumab (N=14 patients).
Drug: DRP-104

DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off

DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week


Biological: atezolizumab
atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD [ Time Frame: anticipated 1 year ]
    Safety

  2. Area under the plasma concentration versus time curve (AUC) [ Time Frame: anticipated 1 year ]
  3. Cmax of DRP-104 [ Time Frame: anticipated 1 year ]

Secondary Outcome Measures :
  1. Overall Response Rate [ Time Frame: anticipated 2 year ]
  2. Disease control rate [ Time Frame: anticipated 2 year ]
  3. Duration of response [ Time Frame: anticipated 2 year ]
  4. Progression-free survival [ Time Frame: anticipated 2 year ]
  5. Overall survival (OS) [ Time Frame: anticipated 2 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of advanced or recurrent, histologically or cytologically confirmed, measurable by RECIST 1.1 metastatic or unresectable solid tumor
  • Patient must have progressed on, be intolerant of, decline, or be ineligible for, all available standard of care therapies
  • Part 2: locally advanced or metastatic NSCLC with KEAP1, NFE2L2 and/or STK11 mutation ; Patients must have received at least a platinum doublet chemotherapy and an anti-PD-(L)1 antibody; Received up to 3 lines of systemic anticancer therapy in the recurrent or metastatic setting
  • Part 2: Recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) (oropharynx, oral cavity, hypopharynx or larynx); Patient must have received platinum containing chemotherapy and antiPD-(L)1 antibody in recurrent or metastatic setting
  • Part 3 and 4 - DRP-104 + atezolizumab Prior exposure to any checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PDL2, and/or anti-CTLA-4 antibody)
  • ECOG performance 0 or 1
  • Patient must consent to allow acquisition of existing FFPE tumor tissue; If unavailable, patient must consent to new pre-treatment tumor biopsy
  • All SCCHN patient, all NSCLC patients and all patients treated with combination of DRP-104 and atezolizumab will be required to undergo pre-treatment and post-treatment core or excisional biopsies.
  • Pre-treatment and post-treatment core or excisional biopsies are optional for all remaining patients
  • Adequate baseline organ function as defined by: Absolute neutrophil count ≥ 1.5 × 109/L (1500/µL); Hemoglobin ≥ 9 g/dL ;Platelets ≥ 75 × 109/L (75,000/µL); Hepatic Total bilirubin ≤1.5 × upper limit of normal (ULN): PT/INR and PTT ≤1.5 × ULN, unless treated with warfarin; AST(SGOT)/ALT(SGPT) ≤3 × ULN or ≤ 5 × ULN for patients with liver metastases; Creatinine clearance ≥ 60 ml/min/1.73m2 measured or calculated
  • Cardiac QTc (Fridericia) <470 ms
  • Women of child-bearing potential and men who are sexually active must agree to use one highly effective method of contraception

Exclusion Criteria:

  • Patients with primary central nervous system tumors and hepatocellular carcinoma
  • Patients with progressive or symptomatic brain metastases
  • Leptomeningeal disease
  • Spinal cord compression not definitively treated with surgery and/or radiation
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage
  • Prior glutaminase inhibitor use
  • Prior systemic anticancer treatment (i.e. chemotherapy, biologic therapy, monoclonal antibodies, investigational agents) within 21 days or 5 half-lives, whichever is shorter
  • Anti-androgen therapies for prostate cancer, such as bicalutamide, within 4 weeks prior to enrollment
  • Prior small port palliative radiotherapy within 14 days of start of Cycle 1
  • Any major surgery within 21 days from start of Cycle 1
  • Secondary malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
  • Has a known history of HIV, or HBV
  • Gastrointestinal (GI) function impairment or GI disease
  • Significant, uncontrolled heart disease and/or cardiac repolarization abnormality
  • Exclusion specific to only Part 3 and 4 (DRP-104 combined with atezolizumab): History of severe allergic, anaphylactic to chimeric or humanized antibodies or fusion proteins; Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells; Prior anti-PD-1, anti-PD-L1 and/or anti CTLA4- agent, patient must not have had a serious (> Grade 3) immune-related AE requiring treatment; History of autoimmune disease except hypothyroidism on thyroid replacement hormone therapy; History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis; Patients with underlying condition requiring systemic corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications or other systemic immunosuppressant medications may be enrolled in the study after approval by the Medical Monitor; Evidence or history of active or latent tuberculosis infection; Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04471415


Contacts
Layout table for location contacts
Contact: Margaret Dugan, MD 973-489-7163 mdugan@dracenpharma.com
Contact: Francois Lafleur, MPH 917-330-3971 FLafleur@dracenpharma.com

Locations
Layout table for location information
United States, Arizona
HonorHealth Recruiting
Scottsdale, Arizona, United States, 85258
Principal Investigator: Sunil Sharma, MD         
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90095
Principal Investigator: Aaron Lisberg, MD         
United States, Maryland
Johns Hopkins Kimmel Institute Recruiting
Baltimore, Maryland, United States, 21231
Principal Investigator: Tanguy Siewert, MD         
United States, New York
NYU Langone Not yet recruiting
New York, New York, United States, 10016
Principal Investigator: Vamsidhar Velcheti, MD         
Mount Sinai Health Systems Recruiting
New York, New York, United States, 10029-6574
Principal Investigator: Deborah Doroshow, MD         
United States, North Carolina
University of North Carolina Not yet recruiting
Chapel Hill, North Carolina, United States, 27514
Principal Investigator: Shetal Patel, MD         
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Principal Investigator: Melissa Johnson, MD         
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Principal Investigator: Michael Gibson, MD         
Germany
Centrum fur Integrieerte Onkologie Not yet recruiting
Cologne, Germany, 50924
Contact: MD         
Principal Investigator: Matthias Scheffler, MD         
Sub-Investigator: Jurgen Wolfe, MD         
Sponsors and Collaborators
Dracen Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Sunil Sharma, MD HonorHealth Director
Additional Information:
Layout table for additonal information
Responsible Party: Dracen Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04471415    
Other Study ID Numbers: DRA-104-001
2020-002770-27 ( EudraCT Number )
First Posted: July 15, 2020    Key Record Dates
Last Update Posted: April 13, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of Head and Neck
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Head and Neck Neoplasms
Atezolizumab
Antineoplastic Agents